[1] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[2] |
ZHANG Yu, ZHANG Wei, GAO Shuangrong, CHEN Mengping, WANG Yaxin, XU Yingli, CAO Shan, ZHAO Ronghua, BAO Lei, LI Shuran, SUN Jing, BAO Yanyan, GENG Zihan, GUO Shanshan, JI Zuen, CUI Xiaolan.
Screening and analysis of host factors interacting with NS1 proteins of influenza A virus based on the proteome chip
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 40-44.
|
[3] |
XIONG Weiyi, REN Jingtian.
Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
|
[4] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[5] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[6] |
ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan.
Comparison standard terminology for pharmaceutical dose forms
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
|
[7] |
MA Qihong, SHI Yuanyuan, CHEN Fangfang, WU Kang, BU Zixuan, LU Tiangong.
Mechanisms of celastrol for ovarian cancer: based on quantitative proteomics
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 721-727.
|
[8] |
PAN Zhemin, XU Sheng, ZHENG Yi, CHEN Chenxin, LIU Yongmei, ZHANG Pengpeng, YE Xiaofei, HE Jia.
Comparison of likelihood ratio tests in post-marketing safety surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 655-660.
|
[9] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[10] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[11] |
LIU Jie, LIU Shengwei, REN Zhongyang, DING Ling, CHEN Chang, HU Yi.
Effects of Panax notoginseng on gene expressions in rats with cerebral ischemia-reperfusion injury based on bioinformatics
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 454-459.
|
[12] |
LIN Ni, YE Qian, GENG Xingchao, WANG Xue, JIN Hongtao, WEN Hairuo.
Genotoxicity of 5-hydroxymethylfurfural and its dipolymer and metabolite
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 157-162.
|
[13] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[14] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[15] |
LEI Chao, QIAO Meng, CHEN Zijia, ZHANG Qiang, XIE Yanming, WANG Zhifei.
Revision of safety information in instructions of traditional Chinese patent medicines and simple preparations
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1396-1400.
|